AKD1 Inhibitors
Chemical inhibitors of AKD1 encompass a range of compounds that interact with various signaling pathways and enzymes to modulate the activity of AKD1. Palbociclib, for instance, targets cyclin-dependent kinases CDK4 and CDK6, which are essential for the progression of the cell cycle. By inhibiting these kinases, Palbociclib can indirectly reduce AKD1 activity, which is implicated in cell cycle regulation. Similarly, Rapamycin forms a complex with FKBP12 to inhibit the mTOR pathway, a crucial regulator of protein synthesis and cell growth. The suppression of mTOR by Rapamycin can lead to a decrease in the cellular growth signals that would normally involve AKD1 activity. Another compound, LY294002, directly inhibits phosphoinositide 3-kinases (PI3K), which are part of the AKT signaling pathway. Given that AKD1 activity is connected to this pathway, the inhibition of PI3K can lead to a reduction in AKD1 activity. Additionally, U0126 and PD98059 both target the MEK1/2 enzymes in the MAPK/ERK pathway. Their action prevents the activation of downstream molecules that would otherwise modulate AKD1 activity associated with this pathway.
Continuing with the theme of kinase inhibition, SB203580 acts on p38 MAP kinase, which is involved in the cell's response to stress and inflammation. By inhibiting p38 MAPK, SB203580 can interfere with the regulation of AKD1 activity that is modulated through stress-related signaling. Wortmannin, akin to LY294002, is another PI3K inhibitor that impedes the PI3K/AKT signaling cascade, thereby suppressing AKD1 activity that is influenced by this pathway. Triciribine specifically targets the AKT signaling pathway, which is paramount in regulating cell survival and metabolism, leading to a decrease in AKD1 activity. On a similar note, SP600125 inhibits c-Jun N-terminal kinase (JNK), involved in apoptosis and proliferation, which can also result in reduced AKD1 activity. Gefitinib, an EGFR tyrosine kinase inhibitor, disrupts the EGFR signaling that regulates several cellular processes that could engage AKD1. Lastly, ZM336372 inhibits c-Raf of the MAPK/ERK pathway, further contributing to the downregulation of AKD1 activity due to the diminished activity of this pathway. Collectively, these inhibitors demonstrate diverse mechanisms by which AKD1 activity can be regulated through the modulation of intracellular signaling.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib selectively inhibits cyclin-dependent kinases CDK4 and CDK6 which are involved in cell cycle progression. AKD1 is implicated in cell cycle regulation, and inhibition of CDK4/6 can lead to reduced AKD1 activity due to halted cell cycle progression where AKD1 is active. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and together they inhibit mTOR (mammalian target of rapamycin), a kinase that is part of the regulatory pathway that controls protein synthesis and cell growth. As AKD1 is involved in cell growth pathways, mTOR inhibition can decrease AKD1 activity by reducing the cellular growth signals that AKD1 would typically be involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits phosphoinositide 3-kinases (PI3K), which play a crucial role in the AKT signaling pathway. AKD1 is connected to the AKT pathway, and by inhibiting PI3K, LY294002 can reduce AKT pathway activity, leading to a decrease in AKD1 activity that is regulated by this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are kinases involved in the MAPK/ERK signaling pathway. AKD1 has been associated with the MAPK/ERK pathway, and by inhibiting MEK1/2, U0126 can suppress the pathway's activity, thereby inhibiting AKD1 function that is dependent on this signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. The p38 MAPK signaling pathway is involved in inflammatory responses and stress, which can regulate the activity of a variety of proteins, including AKD1. By inhibiting p38 MAPK, SB203580 can inhibit AKD1 activity that is modulated by stress and inflammation-related signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor, similar to LY294002. It blocks the PI3K/AKT signaling pathway, which is crucial for many cellular processes including growth and survival where AKD1 may be active. By inhibiting PI3K, Wortmannin can suppress AKD1 activity that is modulated by the PI3K/AKT pathway. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits the AKT signaling pathway, which is involved in cell survival and metabolism. AKD1 activity is influenced by AKT pathway signaling, and by inhibiting this pathway, Triciribine can decrease AKD1 activity that is controlled by AKT-mediated signals. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in the regulation of apoptosis and cell proliferation. AKD1, being part of cellular signaling pathways, can be influenced by JNK activity. Inhibiting JNK with SP600125 can lead to a reduction in AKD1 activity, as JNK signaling can regulate proteins involved in growth and apoptosis where AKD1 functions. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the activation of ERK, which is part of the MAPK/ERK pathway. Since AKD1 is associated with the MAPK/ERK signaling, inhibition of MEK by PD98059 can lead to the reduction in AKD1 activity as a result of suppressed ERK signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. EGFR signaling is known to regulate various cellular processes including growth and survival, which can impact AKD1 activity. By inhibiting EGFR, Gefitinib can reduce the downstream signaling events that would otherwise enhance AKD1 activity through growth factor-mediated pathways. | ||||||